Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome

Haematologica. 2024 Jun 1;109(6):1984-1988. doi: 10.3324/haematol.2023.284429.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • CD3 Complex*
  • CD4 Antigens / metabolism
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Female
  • Humans
  • Hypereosinophilic Syndrome* / diagnosis
  • Hypereosinophilic Syndrome* / drug therapy
  • Hypereosinophilic Syndrome* / pathology
  • Male
  • Middle Aged
  • Receptors, CCR4* / antagonists & inhibitors
  • Receptors, CCR4* / metabolism
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • mogamulizumab
  • Receptors, CCR4
  • CD3 Complex
  • CCR4 protein, human
  • CD4 Antigens